eurofins scientific se - ERFSF

ERFSF

Close Chg Chg %
76.37 1.85 2.42%

Closed Market

78.22

+1.85 (2.42%)

Volume: 1.00K

Last Updated:

Apr 2, 2026, 3:51 PM EDT

Company Overview: eurofins scientific se - ERFSF

ERFSF Key Data

Open

$74.45

Day Range

74.45 - 78.22

52 Week Range

48.55 - 86.20

Market Cap

$13.34B

Shares Outstanding

170.53M

Public Float

105.08M

Beta

0.72

Rev. Per Employee

N/A

P/E Ratio

26.25

EPS

$0.54

Yield

83.04%

Dividend

$0.68

EX-DIVIDEND DATE

Apr 28, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

5.35K

 

ERFSF Performance

1 Week
 
4.81%
 
1 Month
 
0.63%
 
3 Months
 
5.03%
 
1 Year
 
46.17%
 
5 Years
 
-26.15%
 

ERFSF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About eurofins scientific se - ERFSF

Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.

ERFSF At a Glance

Eurofins Scientific SE
23 Val Fleuri
Luxembourg, Luxembourg 1526
Phone 352-26-18-53-20 Revenue 8.23B
Industry Miscellaneous Commercial Services Net Income 535.85M
Sector Commercial Services 2025 Sales Growth 9.515%
Fiscal Year-end 12 / 2026 Employees 65,694
View SEC Filings

ERFSF Valuation

P/E Current 26.246
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.591
Price to Sales Ratio 1.66
Price to Book Ratio 3.112
Price to Cash Flow Ratio 9.36
Enterprise Value to EBITDA 11.014
Enterprise Value to Sales 2.327
Total Debt to Enterprise Value 0.333

ERFSF Efficiency

Revenue/Employee 125,342.004
Income Per Employee 8,156.739
Receivables Turnover 4.265
Total Asset Turnover 0.681

ERFSF Liquidity

Current Ratio 1.092
Quick Ratio 1.035
Cash Ratio 0.326

ERFSF Profitability

Gross Margin 12.29
Operating Margin 11.216
Pretax Margin 8.961
Net Margin 6.508
Return on Assets 4.433
Return on Equity 12.383
Return on Total Capital 5.083
Return on Invested Capital 5.806

ERFSF Capital Structure

Total Debt to Total Equity 153.303
Total Debt to Total Capital 60.522
Total Debt to Total Assets 49.447
Long-Term Debt to Equity 132.794
Long-Term Debt to Total Capital 52.425
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Eurofins Scientific Se - ERFSF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
7.05B 7.04B 7.52B 8.23B
Sales Growth
-11.16% -0.16% +6.76% +9.51%
Cost of Goods Sold (COGS) incl D&A
6.19B 6.37B 6.66B 7.22B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
638.15M 718.19M 747.88M 815.85M
Depreciation
468.52M 543.04M 570.16M 632.57M
Amortization of Intangibles
169.63M 175.14M 177.72M 183.28M
COGS Growth
-2.41% +2.98% +4.51% +8.44%
Gross Income
866.32M 670.72M 858.86M 1.01B
Gross Income Growth
-45.83% -22.58% +28.05% +17.83%
Gross Profit Margin
+12.28% +9.52% +11.42% +12.29%
2022 2023 2024 2025 5-year trend
SG&A Expense
41.41M 79.57M 73.34M 88.48M
Research & Development
- - - -
-
Other SG&A
41.41M 79.57M 73.34M 88.48M
SGA Growth
-41.90% +92.16% -7.83% +20.65%
Other Operating Expense
- - - -
-
Unusual Expense
11.14M 16.65M 11.79M 38.60M
EBIT after Unusual Expense
813.77M 574.50M 773.73M 884.92M
Non Operating Income/Expense
97.85M 11.03M (21.63M) 21.44M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
92.80M 128.33M 153.28M 168.50M
Interest Expense Growth
-54.51% +38.28% +19.44% +9.93%
Gross Interest Expense
92.80M 128.33M 153.28M 168.50M
Interest Capitalized
- - - -
-
Pretax Income
818.81M 457.20M 598.82M 737.86M
Pretax Income Growth
-34.31% -44.16% +30.98% +23.22%
Pretax Margin
+11.61% +6.49% +7.96% +8.96%
Income Tax
183.08M 124.87M 161.28M 204.39M
Income Tax - Current - Domestic
211.46M 169.63M 200.11M 185.65M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(28.38M) (44.76M) (38.83M) 18.73M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
636.68M 332.77M 438.63M 533.82M
Minority Interest Expense
(4.62M) (2.70M) (973.52K) (2.03M)
Net Income
641.30M 335.47M 439.60M 535.85M
Net Income Growth
-30.67% -47.69% +31.04% +21.89%
Net Margin Growth
+9.09% +4.76% +5.85% +6.51%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
641.30M 335.47M 439.60M 535.85M
Preferred Dividends
- - - -
-
Net Income Available to Common
641.30M 335.36M 439.60M 535.85M
EPS (Basic)
3.3315 1.7385 2.3064 2.9802
EPS (Basic) Growth
-31.03% -47.82% +32.67% +29.21%
Basic Shares Outstanding
192.50M 192.90M 190.60M 179.80M
EPS (Diluted)
3.2226 1.6946 2.2601 2.8732
EPS (Diluted) Growth
-30.12% -47.42% +33.37% +27.13%
Diluted Shares Outstanding
199.00M 197.90M 194.50M 186.50M
EBITDA
1.46B 1.31B 1.53B 1.74B
EBITDA Growth
-31.91% -10.51% +17.11% +13.43%
EBITDA Margin
+20.74% +18.59% +20.39% +21.12%

Eurofins Scientific Se in the News